Biotechnology company Allergy Therapeutics (AIM: AGY) announced on Monday that it has published Phase III trial data for its subcutaneous immunotherapy Grass MATA MPL in the journal Allergy. The study demonstrated a 20.3% reduction in Combined Symptom & Medication Score (CSMS) versus placebo (p=0.0005) over the peak pollen season, supporting a recent Marketing Authorisation Application to Germany's Paul Ehrlich Institut.

Grass MATA MPL is a short-course, aluminium-free pre-seasonal immunotherapy requiring just six injections before the grass allergy season. The publication provides mechanistic insights, showing it triggers IgG4 and IgA antibody responses, enhancing its efficacy compared to other treatments. Patients reported a 27.7% improvement in rhinitis-related quality of life, outperforming other grass allergy immunotherapies.

No other subcutaneous immunotherapy for respiratory allergies has surpassed 14% efficacy improvement in Phase III trials over the past decade. The six-injection regimen achieved >95% trial completion, contrasting with traditional treatments requiring up to 100 injections or years of daily tablets.

Allergy Therapeutics, headquartered in the UK, develops and commercialises allergy immunotherapies across Europe and international markets. Grass MATA MPL is designed to treat allergic rhinoconjunctivitis caused by grass pollen, with a mode of action involving allergoids, microcrystalline tyrosine and monophosphoryl lipid-A to enhance immune response.